Our Portfolio

We are advancing multiple mono-strain Live Biotherapeutics product candidates using a specific natural-occurring strain of Faecalibacterium Prausnitzii into clinical studies across inflammatory bowel diseases.

In parallel, we are also working on isolating new bacteria candidates to treat a wider range of diseases.

* NBX1650 is a mono-strain microbial product candidate using Faecalibacterium prausnitzii